iSpecimen Inc. Deferred Offering Costs
iSpecimen Inc. (ISPC) had Deferred Offering Costs of $0 as of 2021-12-31, per its 10-K filed 2022-03-22.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2022-03-22
- 2021-12-31: Deferred Offering Costs $0.00.
- 2021-09-30: Deferred Offering Costs $0.00.
- 2021-06-30: Deferred Offering Costs $0.00.
- 2021-06-21: Deferred Offering Costs $2.30M; Deferred Offering Costs as first filed $600.00K.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-22 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-10 | |
| 2021-06-21 | $2.30M 10-K · filed 2022-03-22 | $600.00K 10-Q · filed 2021-08-10 |
| 2020-12-31 | $265.00K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |